V66-exatecan significantly inhibited tumor growth and extended survival in both TNBC. »
10/13/25

Higher mCAF frequencies independent prognostic factor for decreased RFP and DCR. »
10/13/25

SBRT of liver metastases associated with minor alterations in metabolic liver function. »
10/13/25

Association between survival benefit and ACT timing varied based on risk levels. »
10/14/25

Compression therapy using standard gloves and stockings appears tolerable. »
10/14/25

Greater subcutaneous adiposity at T4 showed non-significant trend toward increased mortality. »
10/14/25

FASN suppresses ferroptosis in BC by stabilizing GPX4 via USP5-mediated mechanisms. »
10/14/25

Thyroid hormone (TH) signaling plays a major role in the development, energy homeostasis, and metabolism of most tissues. Recent studies have identified THs as drivers of prostate cancer (PCa) development and progression. We reported that the T3-scavenger protein µ-crystallin (CRYM) regulates the development and progression of PCa and that this involved crosstalk with androgen receptor (AR) signaling. However, the mechanisms remain incompletely understood. Here, we explored the role of thyroid hormone receptor β (TRβ), which is the main effector of TH signaling, in the context of PCa. The use of the TRβ-selective antagonist NH-3 inhibited PCa cell proliferation in vitro and reduced tumor size in PCa xenograft models in vivo. Notably, NH-3 was highly effective in the engrafted 22Rv1 cell line, a model for castration-resistant PCa (CRPC). Mechanistic studies revealed that NH-3 downregulates AR and the AR target genes Nkx3.1 and KLK3 (PSA). NH-3 was a more effective anticancer agent than enzalutamide, and their combined use was synergistic. Evidence from human datasets corroborates our findings, whereby elevated TRβ expression and mutations in the TH signaling pathway are associated with the onset of PCa. Collectively, these results establish TRβ as a mediator of tumorigenesis in PCa and identify NH-3 as a promising therapeutic agent for targeting AR signaling, particularly in CRPC. »
10/14/25

PLK4 expression greater in DLBCL tissue. »
10/14/25

Opioid-receptor-mu-1 mRNA levels elevated in CIPN-negative patients. »
10/15/25